Department of Community Health Sciences and Hotchkiss Brain Institute Mental Health Centre for Research and Education, University of Calgary, Calgary, Alberta.
Can J Psychiatry. 2012 Apr;57(4):263-8. doi: 10.1177/070674371205700410.
We examined trends in prescription recommendations for treatment of bipolar disorder (BD) in Canada during 2002-2010.
Data collected by IMS Brogan in a database known as the Canadian Disease and Therapeutic Index were used for this analysis. These data are collected from a representative physician panel who record each drug recommendation and reason for recommendation in their practices for 2 consecutive days each calendar quarter of the year. Prescription patterns of medications for BD, including lithium, anticonvulsants, antipsychotic agents, anxiolytics, and antidepressants, were evaluated both for general practitioners and for specialists.
The number of prescription recommendations for BD increased by 72.1% from 2002 to 2009, and then dropped by 24.8% from 2009 to 2010. This increase from 2002 to 2009, and subsequent decrease from 2009 to 2010, was observed for all classes of medications. The overall increase from 2002 to 2010 was statistically significant for the atypical antipsychotics (P = 0.04). The largest change for an individual drug during this period was a 438% increase in recommendations for quetiapine (P = 0.01).
The number of prescription recommendations for BD increased substantially from 2002 to 2009 and sharply dropped in the following year. These results suggest that the influence of the concept of the bipolar spectrum and its promotion may have resulted in a substantial increase in treatment that has recently begun to wane.
我们研究了 2002-2010 年加拿大治疗双相情感障碍（BD）的处方推荐趋势。
这项分析使用了 IMS Brogan 在加拿大疾病和治疗索引数据库中收集的数据。这些数据是从一个代表性的医生小组收集的，他们在每年每个日历季度的连续两天内记录他们实践中的每一种药物推荐和推荐理由。评估了包括锂、抗惊厥药、抗精神病药、抗焦虑药和抗抑郁药在内的 BD 药物的处方模式，包括全科医生和专家。
从 2002 年到 2009 年，BD 的处方推荐数量增加了 72.1%，从 2009 年到 2010 年又下降了 24.8%。从 2002 年到 2009 年的增加，以及随后从 2009 年到 2010 年的减少，在所有药物类别中都观察到。从 2002 年到 2010 年的总体增长在非典型抗精神病药方面具有统计学意义（P=0.04）。在此期间，个别药物的最大变化是喹硫平的推荐增加了 438%（P=0.01）。
从 2002 年到 2009 年，BD 的处方推荐数量大幅增加，次年急剧下降。这些结果表明，双相谱概念及其推广的影响可能导致治疗量大幅增加，而这种情况最近开始减弱。
